 | • レポートコード：QYR2104Z2244 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、116ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、肢端紅痛症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（治療薬、治療）、用途別市場規模（原発性肢端紅痛症、続発性肢端紅痛症）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・肢端紅痛症治療の市場動向 ・企業の競争状況、市場シェア ・肢端紅痛症治療の種類別市場規模（治療薬、治療） ・肢端紅痛症治療の用途別市場規模（原発性肢端紅痛症、続発性肢端紅痛症） ・肢端紅痛症治療の北米市場規模2016-2027（アメリカ、カナダ） ・肢端紅痛症治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・肢端紅痛症治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・肢端紅痛症治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・肢端紅痛症治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Teva Pharmaceutical Industries Ltd、Biogen、Pfizer Inc、Akorn、Novartis AG、Galderma SA、Acorda Therapeutics, Inc、AbbVie、Amneal Pharmaceuticals LLC、Xenon Pharmaceuticals Inc、Ligand Pharmaceuticals Incorporated、Zydus Cadila、ANI Pharmaceuticals, Inc、Lupin Limited、Bausch Health、Indoco Remedies Ltd） ・結論 |
Erythromelalgia is a rare condition that primarily affects the feet and it is characterized by intense, burning pain of affected extremities, severe redness (erythema), and increased skin temperature that may be episodic or almost continuous in nature.The specific cause of erythromelalgia remains unknown. Erythromelalgia is a result of vasomotor abnormalities or dysfunction in the normal narrowing and widening of the diameter of certain blood vessels, leading to abnormalities of blood flow to the extremities.Females are more affected than males. Disorder onset occurs most commonly in middle age; however, associated symptoms may develop at any age.
Market Analysis and Insights: Global Erythromelalgia Treatment Market
The global Erythromelalgia Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Erythromelalgia Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Erythromelalgia Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Erythromelalgia Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Erythromelalgia Treatment market.
Global Erythromelalgia Treatment Scope and Market Size
Erythromelalgia Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Erythromelalgia Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
by Treatment
Drugs
Therapy
by Route of Administration
Oral
Inhalation
Others
Segment by Application
Primary Erythromelalgia
Secondary Erythromelalgia
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Teva Pharmaceutical Industries Ltd
Biogen
Pfizer Inc
Akorn
Novartis AG
Galderma SA
Acorda Therapeutics, Inc
AbbVie
Amneal Pharmaceuticals LLC
Xenon Pharmaceuticals Inc
Ligand Pharmaceuticals Incorporated
Zydus Cadila
ANI Pharmaceuticals, Inc
Lupin Limited
Bausch Health
Indoco Remedies Ltd
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Erythromelalgia Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Drugs
1.2.3 Therapy
1.3 Market by Application
1.3.1 Global Erythromelalgia Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Primary Erythromelalgia
1.3.3 Secondary Erythromelalgia
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Erythromelalgia Treatment Market Perspective (2016-2027)
2.2 Erythromelalgia Treatment Growth Trends by Regions
2.2.1 Erythromelalgia Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Erythromelalgia Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Erythromelalgia Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Erythromelalgia Treatment Industry Dynamic
2.3.1 Erythromelalgia Treatment Market Trends
2.3.2 Erythromelalgia Treatment Market Drivers
2.3.3 Erythromelalgia Treatment Market Challenges
2.3.4 Erythromelalgia Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Erythromelalgia Treatment Players by Revenue
3.1.1 Global Top Erythromelalgia Treatment Players by Revenue (2016-2021)
3.1.2 Global Erythromelalgia Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Erythromelalgia Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Erythromelalgia Treatment Revenue
3.4 Global Erythromelalgia Treatment Market Concentration Ratio
3.4.1 Global Erythromelalgia Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Erythromelalgia Treatment Revenue in 2020
3.5 Erythromelalgia Treatment Key Players Head office and Area Served
3.6 Key Players Erythromelalgia Treatment Product Solution and Service
3.7 Date of Enter into Erythromelalgia Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Erythromelalgia Treatment Breakdown Data by Type
4.1 Global Erythromelalgia Treatment Historic Market Size by Type (2016-2021)
4.2 Global Erythromelalgia Treatment Forecasted Market Size by Type (2022-2027)
5 Erythromelalgia Treatment Breakdown Data by Application
5.1 Global Erythromelalgia Treatment Historic Market Size by Application (2016-2021)
5.2 Global Erythromelalgia Treatment Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Erythromelalgia Treatment Market Size (2016-2027)
6.2 North America Erythromelalgia Treatment Market Size by Type
6.2.1 North America Erythromelalgia Treatment Market Size by Type (2016-2021)
6.2.2 North America Erythromelalgia Treatment Market Size by Type (2022-2027)
6.2.3 North America Erythromelalgia Treatment Market Size by Type (2016-2027)
6.3 North America Erythromelalgia Treatment Market Size by Application
6.3.1 North America Erythromelalgia Treatment Market Size by Application (2016-2021)
6.3.2 North America Erythromelalgia Treatment Market Size by Application (2022-2027)
6.3.3 North America Erythromelalgia Treatment Market Size by Application (2016-2027)
6.4 North America Erythromelalgia Treatment Market Size by Country
6.4.1 North America Erythromelalgia Treatment Market Size by Country (2016-2021)
6.4.2 North America Erythromelalgia Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Erythromelalgia Treatment Market Size (2016-2027)
7.2 Europe Erythromelalgia Treatment Market Size by Type
7.2.1 Europe Erythromelalgia Treatment Market Size by Type (2016-2021)
7.2.2 Europe Erythromelalgia Treatment Market Size by Type (2022-2027)
7.2.3 Europe Erythromelalgia Treatment Market Size by Type (2016-2027)
7.3 Europe Erythromelalgia Treatment Market Size by Application
7.3.1 Europe Erythromelalgia Treatment Market Size by Application (2016-2021)
7.3.2 Europe Erythromelalgia Treatment Market Size by Application (2022-2027)
7.3.3 Europe Erythromelalgia Treatment Market Size by Application (2016-2027)
7.4 Europe Erythromelalgia Treatment Market Size by Country
7.4.1 Europe Erythromelalgia Treatment Market Size by Country (2016-2021)
7.4.2 Europe Erythromelalgia Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Erythromelalgia Treatment Market Size (2016-2027)
8.2 Asia-Pacific Erythromelalgia Treatment Market Size by Type
8.2.1 Asia-Pacific Erythromelalgia Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Erythromelalgia Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Erythromelalgia Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Erythromelalgia Treatment Market Size by Application
8.3.1 Asia-Pacific Erythromelalgia Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Erythromelalgia Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Erythromelalgia Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Erythromelalgia Treatment Market Size by Region
8.4.1 Asia-Pacific Erythromelalgia Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Erythromelalgia Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Erythromelalgia Treatment Market Size (2016-2027)
9.2 Latin America Erythromelalgia Treatment Market Size by Type
9.2.1 Latin America Erythromelalgia Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Erythromelalgia Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Erythromelalgia Treatment Market Size by Type (2016-2027)
9.3 Latin America Erythromelalgia Treatment Market Size by Application
9.3.1 Latin America Erythromelalgia Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Erythromelalgia Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Erythromelalgia Treatment Market Size by Application (2016-2027)
9.4 Latin America Erythromelalgia Treatment Market Size by Country
9.4.1 Latin America Erythromelalgia Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Erythromelalgia Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Erythromelalgia Treatment Market Size (2016-2027)
10.2 Middle East & Africa Erythromelalgia Treatment Market Size by Type
10.2.1 Middle East & Africa Erythromelalgia Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Erythromelalgia Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Erythromelalgia Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Erythromelalgia Treatment Market Size by Application
10.3.1 Middle East & Africa Erythromelalgia Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Erythromelalgia Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Erythromelalgia Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Erythromelalgia Treatment Market Size by Country
10.4.1 Middle East & Africa Erythromelalgia Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Erythromelalgia Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Teva Pharmaceutical Industries Ltd
11.1.1 Teva Pharmaceutical Industries Ltd Company Details
11.1.2 Teva Pharmaceutical Industries Ltd Business Overview
11.1.3 Teva Pharmaceutical Industries Ltd Erythromelalgia Treatment Introduction
11.1.4 Teva Pharmaceutical Industries Ltd Revenue in Erythromelalgia Treatment Business (2016-2021)
11.1.5 Teva Pharmaceutical Industries Ltd Recent Development
11.2 Biogen
11.2.1 Biogen Company Details
11.2.2 Biogen Business Overview
11.2.3 Biogen Erythromelalgia Treatment Introduction
11.2.4 Biogen Revenue in Erythromelalgia Treatment Business (2016-2021)
11.2.5 Biogen Recent Development
11.3 Pfizer Inc
11.3.1 Pfizer Inc Company Details
11.3.2 Pfizer Inc Business Overview
11.3.3 Pfizer Inc Erythromelalgia Treatment Introduction
11.3.4 Pfizer Inc Revenue in Erythromelalgia Treatment Business (2016-2021)
11.3.5 Pfizer Inc Recent Development
11.4 Akorn
11.4.1 Akorn Company Details
11.4.2 Akorn Business Overview
11.4.3 Akorn Erythromelalgia Treatment Introduction
11.4.4 Akorn Revenue in Erythromelalgia Treatment Business (2016-2021)
11.4.5 Akorn Recent Development
11.5 Novartis AG
11.5.1 Novartis AG Company Details
11.5.2 Novartis AG Business Overview
11.5.3 Novartis AG Erythromelalgia Treatment Introduction
11.5.4 Novartis AG Revenue in Erythromelalgia Treatment Business (2016-2021)
11.5.5 Novartis AG Recent Development
11.6 Galderma SA
11.6.1 Galderma SA Company Details
11.6.2 Galderma SA Business Overview
11.6.3 Galderma SA Erythromelalgia Treatment Introduction
11.6.4 Galderma SA Revenue in Erythromelalgia Treatment Business (2016-2021)
11.6.5 Galderma SA Recent Development
11.7 Acorda Therapeutics, Inc
11.7.1 Acorda Therapeutics, Inc Company Details
11.7.2 Acorda Therapeutics, Inc Business Overview
11.7.3 Acorda Therapeutics, Inc Erythromelalgia Treatment Introduction
11.7.4 Acorda Therapeutics, Inc Revenue in Erythromelalgia Treatment Business (2016-2021)
11.7.5 Acorda Therapeutics, Inc Recent Development
11.8 AbbVie
11.8.1 AbbVie Company Details
11.8.2 AbbVie Business Overview
11.8.3 AbbVie Erythromelalgia Treatment Introduction
11.8.4 AbbVie Revenue in Erythromelalgia Treatment Business (2016-2021)
11.8.5 AbbVie Recent Development
11.9 Amneal Pharmaceuticals LLC
11.9.1 Amneal Pharmaceuticals LLC Company Details
11.9.2 Amneal Pharmaceuticals LLC Business Overview
11.9.3 Amneal Pharmaceuticals LLC Erythromelalgia Treatment Introduction
11.9.4 Amneal Pharmaceuticals LLC Revenue in Erythromelalgia Treatment Business (2016-2021)
11.9.5 Amneal Pharmaceuticals LLC Recent Development
11.10 Xenon Pharmaceuticals Inc
11.10.1 Xenon Pharmaceuticals Inc Company Details
11.10.2 Xenon Pharmaceuticals Inc Business Overview
11.10.3 Xenon Pharmaceuticals Inc Erythromelalgia Treatment Introduction
11.10.4 Xenon Pharmaceuticals Inc Revenue in Erythromelalgia Treatment Business (2016-2021)
11.10.5 Xenon Pharmaceuticals Inc Recent Development
11.11 Ligand Pharmaceuticals Incorporated
11.11.1 Ligand Pharmaceuticals Incorporated Company Details
11.11.2 Ligand Pharmaceuticals Incorporated Business Overview
11.11.3 Ligand Pharmaceuticals Incorporated Erythromelalgia Treatment Introduction
11.11.4 Ligand Pharmaceuticals Incorporated Revenue in Erythromelalgia Treatment Business (2016-2021)
11.11.5 Ligand Pharmaceuticals Incorporated Recent Development
11.12 Zydus Cadila
11.12.1 Zydus Cadila Company Details
11.12.2 Zydus Cadila Business Overview
11.12.3 Zydus Cadila Erythromelalgia Treatment Introduction
11.12.4 Zydus Cadila Revenue in Erythromelalgia Treatment Business (2016-2021)
11.12.5 Zydus Cadila Recent Development
11.13 ANI Pharmaceuticals, Inc
11.13.1 ANI Pharmaceuticals, Inc Company Details
11.13.2 ANI Pharmaceuticals, Inc Business Overview
11.13.3 ANI Pharmaceuticals, Inc Erythromelalgia Treatment Introduction
11.13.4 ANI Pharmaceuticals, Inc Revenue in Erythromelalgia Treatment Business (2016-2021)
11.13.5 ANI Pharmaceuticals, Inc Recent Development
11.14 Lupin Limited
11.14.1 Lupin Limited Company Details
11.14.2 Lupin Limited Business Overview
11.14.3 Lupin Limited Erythromelalgia Treatment Introduction
11.14.4 Lupin Limited Revenue in Erythromelalgia Treatment Business (2016-2021)
11.14.5 Lupin Limited Recent Development
11.15 Bausch Health
11.15.1 Bausch Health Company Details
11.15.2 Bausch Health Business Overview
11.15.3 Bausch Health Erythromelalgia Treatment Introduction
11.15.4 Bausch Health Revenue in Erythromelalgia Treatment Business (2016-2021)
11.15.5 Bausch Health Recent Development
11.16 Indoco Remedies Ltd
11.16.1 Indoco Remedies Ltd Company Details
11.16.2 Indoco Remedies Ltd Business Overview
11.16.3 Indoco Remedies Ltd Erythromelalgia Treatment Introduction
11.16.4 Indoco Remedies Ltd Revenue in Erythromelalgia Treatment Business (2016-2021)
11.16.5 Indoco Remedies Ltd Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Erythromelalgia Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Drugs
Table 3. Key Players of Therapy
Table 4. Global Erythromelalgia Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Erythromelalgia Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Erythromelalgia Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Erythromelalgia Treatment Market Share by Regions (2016-2021)
Table 8. Global Erythromelalgia Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Erythromelalgia Treatment Market Share by Regions (2022-2027)
Table 10. Erythromelalgia Treatment Market Trends
Table 11. Erythromelalgia Treatment Market Drivers
Table 12. Erythromelalgia Treatment Market Challenges
Table 13. Erythromelalgia Treatment Market Restraints
Table 14. Global Erythromelalgia Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Erythromelalgia Treatment Market Share by Players (2016-2021)
Table 16. Global Top Erythromelalgia Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Erythromelalgia Treatment as of 2020)
Table 17. Ranking of Global Top Erythromelalgia Treatment Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Erythromelalgia Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Erythromelalgia Treatment Product Solution and Service
Table 21. Date of Enter into Erythromelalgia Treatment Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Erythromelalgia Treatment Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Erythromelalgia Treatment Revenue Market Share by Type (2016-2021)
Table 25. Global Erythromelalgia Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Erythromelalgia Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Erythromelalgia Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Erythromelalgia Treatment Revenue Market Share by Application (2016-2021)
Table 29. Global Erythromelalgia Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Erythromelalgia Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Erythromelalgia Treatment Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Erythromelalgia Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Erythromelalgia Treatment Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Erythromelalgia Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Erythromelalgia Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Erythromelalgia Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Erythromelalgia Treatment Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Erythromelalgia Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Erythromelalgia Treatment Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Erythromelalgia Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Erythromelalgia Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Erythromelalgia Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Erythromelalgia Treatment Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Erythromelalgia Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Erythromelalgia Treatment Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Erythromelalgia Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Erythromelalgia Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Erythromelalgia Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Erythromelalgia Treatment Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Erythromelalgia Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Erythromelalgia Treatment Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Erythromelalgia Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Erythromelalgia Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Erythromelalgia Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Erythromelalgia Treatment Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Erythromelalgia Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Erythromelalgia Treatment Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Erythromelalgia Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Erythromelalgia Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Erythromelalgia Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 61. Teva Pharmaceutical Industries Ltd Company Details
Table 62. Teva Pharmaceutical Industries Ltd Business Overview
Table 63. Teva Pharmaceutical Industries Ltd Erythromelalgia Treatment Product
Table 64. Teva Pharmaceutical Industries Ltd Revenue in Erythromelalgia Treatment Business (2016-2021) & (US$ Million)
Table 65. Teva Pharmaceutical Industries Ltd Recent Development
Table 66. Biogen Company Details
Table 67. Biogen Business Overview
Table 68. Biogen Erythromelalgia Treatment Product
Table 69. Biogen Revenue in Erythromelalgia Treatment Business (2016-2021) & (US$ Million)
Table 70. Biogen Recent Development
Table 71. Pfizer Inc Company Details
Table 72. Pfizer Inc Business Overview
Table 73. Pfizer Inc Erythromelalgia Treatment Product
Table 74. Pfizer Inc Revenue in Erythromelalgia Treatment Business (2016-2021) & (US$ Million)
Table 75. Pfizer Inc Recent Development
Table 76. Akorn Company Details
Table 77. Akorn Business Overview
Table 78. Akorn Erythromelalgia Treatment Product
Table 79. Akorn Revenue in Erythromelalgia Treatment Business (2016-2021) & (US$ Million)
Table 80. Akorn Recent Development
Table 81. Novartis AG Company Details
Table 82. Novartis AG Business Overview
Table 83. Novartis AG Erythromelalgia Treatment Product
Table 84. Novartis AG Revenue in Erythromelalgia Treatment Business (2016-2021) & (US$ Million)
Table 85. Novartis AG Recent Development
Table 86. Galderma SA Company Details
Table 87. Galderma SA Business Overview
Table 88. Galderma SA Erythromelalgia Treatment Product
Table 89. Galderma SA Revenue in Erythromelalgia Treatment Business (2016-2021) & (US$ Million)
Table 90. Galderma SA Recent Development
Table 91. Acorda Therapeutics, Inc Company Details
Table 92. Acorda Therapeutics, Inc Business Overview
Table 93. Acorda Therapeutics, Inc Erythromelalgia Treatment Product
Table 94. Acorda Therapeutics, Inc Revenue in Erythromelalgia Treatment Business (2016-2021) & (US$ Million)
Table 95. Acorda Therapeutics, Inc Recent Development
Table 96. AbbVie Company Details
Table 97. AbbVie Business Overview
Table 98. AbbVie Revenue in Erythromelalgia Treatment Business (2016-2021) & (US$ Million)
Table 99. AbbVie Recent Development
Table 100. Amneal Pharmaceuticals LLC Company Details
Table 101. Amneal Pharmaceuticals LLC Business Overview
Table 102. Amneal Pharmaceuticals LLC Erythromelalgia Treatment Product
Table 103. Amneal Pharmaceuticals LLC Revenue in Erythromelalgia Treatment Business (2016-2021) & (US$ Million)
Table 104. Amneal Pharmaceuticals LLC Recent Development
Table 105. Xenon Pharmaceuticals Inc Company Details
Table 106. Xenon Pharmaceuticals Inc Business Overview
Table 107. Xenon Pharmaceuticals Inc Erythromelalgia Treatment Product
Table 108. Xenon Pharmaceuticals Inc Revenue in Erythromelalgia Treatment Business (2016-2021) & (US$ Million)
Table 109. Xenon Pharmaceuticals Inc Recent Development
Table 110. Ligand Pharmaceuticals Incorporated Company Details
Table 111. Ligand Pharmaceuticals Incorporated Business Overview
Table 112. Ligand Pharmaceuticals Incorporated Erythromelalgia Treatment Product
Table 113. Ligand Pharmaceuticals Incorporated Revenue in Erythromelalgia Treatment Business (2016-2021) & (US$ Million)
Table 114. Ligand Pharmaceuticals Incorporated Recent Development
Table 115. Zydus Cadila Company Details
Table 116. Zydus Cadila Business Overview
Table 117. Zydus Cadila Erythromelalgia Treatment Product
Table 118. Zydus Cadila Revenue in Erythromelalgia Treatment Business (2016-2021) & (US$ Million)
Table 119. Zydus Cadila Recent Development
Table 120. ANI Pharmaceuticals, Inc Company Details
Table 121. ANI Pharmaceuticals, Inc Business Overview
Table 122. ANI Pharmaceuticals, Inc Erythromelalgia Treatment Product
Table 123. ANI Pharmaceuticals, Inc Revenue in Erythromelalgia Treatment Business (2016-2021) & (US$ Million)
Table 124. ANI Pharmaceuticals, Inc Recent Development
Table 125. Lupin Limited Company Details
Table 126. Lupin Limited Business Overview
Table 127. Lupin Limited Erythromelalgia Treatment Product
Table 128. Lupin Limited Revenue in Erythromelalgia Treatment Business (2016-2021) & (US$ Million)
Table 129. Lupin Limited Recent Development
Table 130. Bausch Health Company Details
Table 131. Bausch Health Business Overview
Table 132. Bausch Health Erythromelalgia Treatment Product
Table 133. Bausch Health Revenue in Erythromelalgia Treatment Business (2016-2021) & (US$ Million)
Table 134. Bausch Health Recent Development
Table 135. Indoco Remedies Ltd Company Details
Table 136. Indoco Remedies Ltd Business Overview
Table 137. Indoco Remedies Ltd Erythromelalgia Treatment Product
Table 138. Indoco Remedies Ltd Revenue in Erythromelalgia Treatment Business (2016-2021) & (US$ Million)
Table 139. Indoco Remedies Ltd Recent Development
Table 140. Research Programs/Design for This Report
Table 141. Key Data Information from Secondary Sources
Table 142. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Erythromelalgia Treatment Market Share by Type: 2020 VS 2027
Figure 2. Drugs Features
Figure 3. Therapy Features
Figure 4. Global Erythromelalgia Treatment Market Share by Application: 2020 VS 2027
Figure 5. Primary Erythromelalgia Case Studies
Figure 6. Secondary Erythromelalgia Case Studies
Figure 7. Erythromelalgia Treatment Report Years Considered
Figure 8. Global Erythromelalgia Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 9. Global Erythromelalgia Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 10. Global Erythromelalgia Treatment Market Share by Regions: 2020 VS 2027
Figure 11. Global Erythromelalgia Treatment Market Share by Regions (2022-2027)
Figure 12. Global Erythromelalgia Treatment Market Share by Players in 2020
Figure 13. Global Top Erythromelalgia Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Erythromelalgia Treatment as of 2020
Figure 14. The Top 10 and 5 Players Market Share by Erythromelalgia Treatment Revenue in 2020
Figure 15. Global Erythromelalgia Treatment Revenue Market Share by Type (2016-2021)
Figure 16. Global Erythromelalgia Treatment Revenue Market Share by Type (2022-2027)
Figure 17. North America Erythromelalgia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 18. North America Erythromelalgia Treatment Market Share by Type (2016-2027)
Figure 19. North America Erythromelalgia Treatment Market Share by Application (2016-2027)
Figure 20. North America Erythromelalgia Treatment Market Share by Country (2016-2027)
Figure 21. United States Erythromelalgia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. Canada Erythromelalgia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Europe Erythromelalgia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Erythromelalgia Treatment Market Share by Type (2016-2027)
Figure 25. Europe Erythromelalgia Treatment Market Share by Application (2016-2027)
Figure 26. Europe Erythromelalgia Treatment Market Share by Country (2016-2027)
Figure 27. Germany Erythromelalgia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. France Erythromelalgia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. U.K. Erythromelalgia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Italy Erythromelalgia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Russia Erythromelalgia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Nordic Erythromelalgia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Asia-Pacific Erythromelalgia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Erythromelalgia Treatment Market Share by Type (2016-2027)
Figure 35. Asia-Pacific Erythromelalgia Treatment Market Share by Application (2016-2027)
Figure 36. Asia-Pacific Erythromelalgia Treatment Market Share by Region (2016-2027)
Figure 37. China Erythromelalgia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Japan Erythromelalgia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. South Korea Erythromelalgia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Southeast Asia Erythromelalgia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. India Erythromelalgia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Australia Erythromelalgia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Latin America Erythromelalgia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Erythromelalgia Treatment Market Share by Type (2016-2027)
Figure 45. Latin America Erythromelalgia Treatment Market Share by Application (2016-2027)
Figure 46. Latin America Erythromelalgia Treatment Market Share by Country (2016-2027)
Figure 47. Mexico Erythromelalgia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Brazil Erythromelalgia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Middle East & Africa Erythromelalgia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Erythromelalgia Treatment Market Share by Type (2016-2027)
Figure 51. Middle East & Africa Erythromelalgia Treatment Market Share by Application (2016-2027)
Figure 52. Middle East & Africa Erythromelalgia Treatment Market Share by Country (2016-2027)
Figure 53. Turkey Erythromelalgia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Saudi Arabia Erythromelalgia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. UAE Erythromelalgia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Teva Pharmaceutical Industries Ltd Revenue Growth Rate in Erythromelalgia Treatment Business (2016-2021)
Figure 57. Biogen Revenue Growth Rate in Erythromelalgia Treatment Business (2016-2021)
Figure 58. Pfizer Inc Revenue Growth Rate in Erythromelalgia Treatment Business (2016-2021)
Figure 59. Akorn Revenue Growth Rate in Erythromelalgia Treatment Business (2016-2021)
Figure 60. Novartis AG Revenue Growth Rate in Erythromelalgia Treatment Business (2016-2021)
Figure 61. Galderma SA Revenue Growth Rate in Erythromelalgia Treatment Business (2016-2021)
Figure 62. Acorda Therapeutics, Inc Revenue Growth Rate in Erythromelalgia Treatment Business (2016-2021)
Figure 63. AbbVie Revenue Growth Rate in Erythromelalgia Treatment Business (2016-2021)
Figure 64. Amneal Pharmaceuticals LLC Revenue Growth Rate in Erythromelalgia Treatment Business (2016-2021)
Figure 65. Xenon Pharmaceuticals Inc Revenue Growth Rate in Erythromelalgia Treatment Business (2016-2021)
Figure 66. Ligand Pharmaceuticals Incorporated Revenue Growth Rate in Erythromelalgia Treatment Business (2016-2021)
Figure 67. Zydus Cadila Revenue Growth Rate in Erythromelalgia Treatment Business (2016-2021)
Figure 68. ANI Pharmaceuticals, Inc Revenue Growth Rate in Erythromelalgia Treatment Business (2016-2021)
Figure 69. Lupin Limited Revenue Growth Rate in Erythromelalgia Treatment Business (2016-2021)
Figure 70. Bausch Health Revenue Growth Rate in Erythromelalgia Treatment Business (2016-2021)
Figure 71. Indoco Remedies Ltd Revenue Growth Rate in Erythromelalgia Treatment Business (2016-2021)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed
世界の二次性副甲状腺機能亢進症治療市場規模・現状・予測（2021年-2027年） Secondary hyperparathyroidism refers to the excessive secretion of parathyroid hormone by the parathyroid glands in response to hypocalcemia and associated hyperplasia of the glands. In the treatment of secondary hyperparathyroidism due to chronic kidney disease on dialysis calcimimetics do not appe…- 世界の原発性免疫不全症治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Primary Immunodeficiency Diseases Treatment Market The global Primary Immunodeficiency Diseases Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in …
- 世界の眼瞼炎治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Blepharitis Treatment Drugs Market The global Blepharitis Treatment Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integrity…
- 世界の眼瞼炎治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Blepharitis Treatment Drugs Market The global Blepharitis Treatment Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integrity…
- 世界の一次進行性多発性硬化症治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Primary Progressive Multiple Sclerosis Treatment Market The global Primary Progressive Multiple Sclerosis Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard ac…